# Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

> **NCT01941745** · PHASE2 · COMPLETED · sponsor: **Tufts Medical Center** · enrollment: 88 (actual)

## Conditions studied

- Respiratory Distress Syndrome in Premature Infant
- Bronchopulmonary Dysplasia

## Interventions

- **DRUG:** Half normal saline
- **DRUG:** Low Dose rhCC10
- **DRUG:** High dose rhCC10

## Key facts

- **NCT ID:** NCT01941745
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2017-08-25
- **Final completion:** 2017-08-25
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2019-09-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941745, "Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01941745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*